Transgene Biotek has informed us that the company has filed two patents for its cancer drug technologies based on its proprietary RNAi platform.
The company has filed its first patent for a liver cancer drug, following excellent results demonstrated in the latest animal studies. It covers a novel technology that employs an AAV vector system genetically modified by Transgene to efficiently express specific microRNA that silence a particular metastasis-promoting gene in liver cancer cells.
Read moreTransgene Biotek Patents for Liver – Breast Cancer Research